Tirzepatide Significantly Reduces BMI in Adolescents With Obesity, Phase III Trial Shows
A new phase III clinical trial indicates that once-weekly tirzepatide, paired with lifestyle interventions, substantially lowers body mass index in adolescents with obesity.
🏥Public HealthPhoto: medpagetoday.com
Key points
- Tirzepatide led to an 18.5% mean BMI reduction at week 72 compared to a 0.5% increase for placebo.
- Over half of the participants on the medication no longer met the clinical threshold for obesity.
- The study enrolled 160 adolescents aged 12 to 17 across multiple international research centers.
Adolescents with obesity or overweight accompanied by related medical complications experienced significant reductions in body mass index (BMI) when treated with once-weekly tirzepatide (Zepbound) alongside a healthy lifestyle intervention, according to the phase III SURMOUNT-ADOLESCENTS trial. Presented at the ObesityWeek annual meeting and published in JAMA, the study evaluated 160 participants between the ages of 12 and under 18 across 31 medical centers in countries including the U.S., Canada, Italy, and Poland.
By week 72, participants receiving tirzepatide achieved an average BMI reduction of 18.5%, compared with a 0.5% increase in the placebo group. Furthermore, 48.1% of those on the medication reached at least a 20% reduction in BMI, and over half (53.5%) no longer met the clinical threshold for obesity. Aaron S. Kelly, PhD, of the University of Minnesota Medical School, and colleagues reported that all ten key secondary outcomes also favored the treatment, including improvements in waist circumference, body weight, and physical functioning.
Editorialists led by William Heerman, MD, MPH, of Vanderbilt Health noted that while these results expand the therapeutic possibilities for pediatric obesity, clinicians should carefully individualize dose titration based on patient response, nutritional adequacy, and side effects rather than reflexively escalating to the maximum tolerated dose.
What to know: The double-blind trial followed participants for 72 weeks with subcutaneous injections. Always consult a qualified healthcare provider for personal medical decisions and treatment options.
Source medpagetoday.com — medpagetoday.com/meetingcoverage/obesityweek/123891 ↗
Read next
❤️Conditions & CareBlood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma
Researchers have identified a specific RNA signature in blood plasma that may help predict how well lymphoma patients respond to CAR T-cell therapy.
🧠AI AnalysisUltraprocessed Diets May Impact Brain Reward Systems in Younger Adults
A Virginia Tech study suggests that individuals aged 18 to 21 may experience changes in brain reward processing after consuming ultraprocessed foods, a response not obser…
🧠Mind & Mental HealthAddressing Body Image and the Reality of Gluteal Anatomy
A personal reflection on the social and psychological impact of body shape, specifically regarding the gluteal region, and the limitations of consumer solutions for perce…
❤️Conditions & CareMigraine and Smoking Linked to Increased Early Stroke Risk in Women
A large-scale study suggests that people who have given birth and experience migraines while also smoking face a significantly higher risk of stroke before age 60.
🔬ResearchCBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities
A double-blind clinical trial published in JAMA Pediatrics indicates that CBD oil provides no significant behavioral improvement for children and teenagers with intellect…
🏃FitnessExpert Advice on Hydration Gear Sparks Debate Among Recreational Runners
Olympic medalist Josh Kerr recently suggested that runners may not require hydration packs for distances under 12 miles, igniting a broader conversation about gear necess…